Researchers invited to gain early access to next-generation platform to optimize single-cell analysis workflows across expanded applications in life science R&D.
Cambridge, UK [27 January 2025]: Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego, CA, USA.
Cyto-Mine® Chroma represents the next generation of Sphere Bio’s industry-leading Cyto-Mine® single-cell analysis platform. The Early Access Program provides an opportunity to be among the first to demo the Cyto-Mine® Chroma for faster project timeline completion and improved outcomes across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy.
Through the program, the Company will collaborate closely with forward-thinking customers to drive innovation and inform the development of future applications and assays on the platform.
Offering enhanced capabilities, including multiplexing and greater assay flexibility, Cyto-Mine® Chroma has been developed to maximize the efficiency and precision of single-cell functional analysis – enabling tens of millions of cells to be screened in a day.
Leveraging a four-color laser and detector system, Cyto-Mine® Chroma expands the number of parameters that can be analyzed for each cell in a single assay. This supports the upcoming launch of the Company’s first multiplexed assay kit, facilitating multiple readouts within a single experiment, optimizing the throughput and precision of cell selection. By accelerating the early selection of superior candidate cells for downstream expansion or further analysis, overall timelines are reduced from months to weeks, while reducing effort and cost.
Sphere Bio will be showcasing Cyto-Mine® Chroma at its booth (#2744) at SLAS2025. Chief Technology Officer, Richard Hammond, will be presenting a Solutions Spotlight demonstrating the new platform’s capabilities on day two of the conference, Tuesday January 28th, 12:00 – 12:20pm.
“The next-generation Cyto-Mine® Chroma platform has been designed to transform single-cell analysis. We are excited to unveil this innovative platform and its Early Access Program at SLAS, the premier event for lab automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating closely with key industry stakeholders and researchers will allow us to ensure our microfluidic technologies meet the evolving needs of the sector, both now and in the future,” commented Dale Levitzke, CEO, Sphere Bio.
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
For more information contact:
Dr Claire Cox
Sphere Bio Ltd.
Tel: +44 (0)7365 209 441
Email: claire.cox@spherebio.com
About Fluidic Sciences and Sphere Bio
Fluidic Sciences develops transformative in‑solution technologies for protein interaction analysis. Its flagship Fluidity One‑M instrument leverages Microfluidic Diffusional Sizing (MDS) to measure binding affinity, stoichiometry, size, and concentration without immobilization—directly in complex backgrounds such as serum, plasma, and lysate.
Sphere Bio technology develops and manufactures single‑cell analysis and monoclonality assurance systems that enable researchers to find, analyze, and isolate the most valuable cells with speed and precision. Its proprietary picodroplet microfluidics and Cyto‑Mine® Chroma multiplexing platform power applications across antibody discovery, cell line development, cell engineering, and cell therapy.
For more information contact:
